Mizuho Securities analyst Difei Yang maintained a Buy rating on Xeris Pharmaceuticals Inc (XERS) today and set a price target of $27. The company’s shares closed yesterday at $20.43.
Yang noted:
“We continue to see Xeris’ glucagon rescue pen as a superior option for the treatment of severe hypoglycemia from a product profile perspective, as we believe there is a higher probability of successfully delivering the full dose to the patient in an emergency situation. Management believes the product could do much better than a 50% market share.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 18.7% and a 48.2% success rate. Yang covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Audentes Therapeutics, and Revance Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Xeris Pharmaceuticals Inc with a $28 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $27.98 and a one-year low of $15.75. Currently, Xeris Pharmaceuticals Inc has an average volume of 84.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Xeris Pharmaceuticals, Inc.is a pharmaceutical company. It offers XeriSol™ and XeriJect™ formulation technologies. The firm focuses on the development of patient-friendly injectable drugs to address unmet medical needs. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Austin, TX.